12 Month Price Forecast For LUMO
Distance to LUMO Price Forecasts
LUMO Price Momentum
🤔 Considering Lumos Pharma (LUMO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 11:52 PM UTC
LUMO Analyst Ratings & Price Targets
Currently, there are no Wall Street analyst price targets or forecasts available for LUMO (Lumos Pharma).
LUMO is currently trading at $0.00. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LUMO Analyst Consensus
LUMO Price Target Range
Latest LUMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LUMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Stocks Similar to
The following stocks are similar to Lumos Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
(LUMO) Financial Data
has a market capitalization of $0 with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
(LUMO) Company Overview
(LUMO) Latest News & Analysis
Lumos Pharma completed a tender offer at $4.25 per share, totaling $38 million. Shareholders receive a CVR linked to future revenue milestones, though payments are not guaranteed.
Lumos Pharma's tender offer at a premium signals potential value recognition and strategic interest in the company, impacting shareholder sentiment and future investment decisions.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
2 months agoMonteverde & Associates is investigating Lumos Pharma's merger with Double Point Ventures, which offers $4.25 per share plus potential contingent value rights based on milestones.
Lumos Pharma's merger with Double Point Ventures at $4.25 per share reflects potential value for shareholders and may influence stock performance and investor sentiment.
Rowley Law PLLC is investigating Lumos Pharma (NASDAQ: LUMO) for potential securities law violations related to its acquisition by Double Point Ventures, offering $4.25 and a contingent value right per share.
The investigation into Lumos Pharma's acquisition raises concerns about possible securities law violations, which could affect stockholder payouts and the company's future performance.
Ademi LLP is investigating Lumos Pharma (NASDAQ: LUMO) for potential fiduciary duty breaches in its deal with Double Point Ventures, offering shareholders $4.25 per share and CVRs.
The investigation into Lumos Pharma may signal potential legal risks and governance issues, possibly impacting stock value and investor confidence in the company.
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
2 months agoHalper Sadeh LLC is investigating the fairness of Lumos Pharma's sale to Double Point Ventures for $4.25 per share and additional contingent value rights for shareholders.
The investigation into Lumos Pharma's sale may indicate potential undervaluation, affecting shareholder sentiment and stock price dynamics, which could influence broader market perceptions.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
2 months agoHalper Sadeh LLC is investigating Martin Midstream Partners L.P. (NASDAQ: MMLP) for potential securities law violations related to its sale to Martin Resource Management at $4.02 per unit.
The investigation into Martin Midstream Partners' sale may indicate potential legal issues or undervaluation, prompting concerns about shareholder rights and future stock performance.
Frequently Asked Questions About LUMO Stock
What is 's (LUMO) stock forecast for 2025?
Analyst forecasts for (LUMO) are not currently available. The stock is trading at $0.00.
Is LUMO stock a good investment in 2025?
Analyst ratings for LUMO are not currently available. The stock is currently trading at $0.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LUMO stock?
Price predictions from Wall Street analysts for LUMO are not currently available. The stock is trading at $0.00.
What is 's business model?
N/A
What is the highest forecasted price for LUMO ?
Price targets from Wall Street analysts for LUMO are not currently available. The stock is trading at $0.00.
What is the lowest forecasted price for LUMO ?
Price targets from Wall Street analysts for LUMO are not currently available. The stock is trading at $0.00.
What is the overall LUMO consensus from analysts for ?
Analyst ratings for LUMO are not currently available. The stock is trading at $0.00.
How accurate are LUMO stock price projections?
Stock price projections, including those for , are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
